Pharmacogenomics and personalized medicine for the developing world - Too soon or just-in-time? A personal view from the World Health Organization

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 3, 2009, Pages 149-157

  Pang, T ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Developing countries; Global health; Personalized medicine; Pharmacogenomics; Public health

Indexed keywords

ABACAVIR; EFAVIRENZ; ISONIAZID; NEVIRAPINE;

ANTIBIOTIC RESISTANCE; BIOETHICS; CLIMATE CHANGE; COMMUNICABLE DISEASE; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG HYPERSENSITIVITY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOMICS; GREENHOUSE EFFECT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH HAZARD; HUMAN; LEGAL ASPECT; LIVER TOXICITY; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; MEDICINE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PUBLIC HEALTH; RASH; RESOURCE MANAGEMENT; REVIEW; SOCIAL ASPECT; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 72449189641     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692110907030149     Document Type: Review

References (72)

1. DNA testing. PJ Net. [Accessed: April 1, 2009]. Available from: http://www.pjnet.com.my/ftopict-11007.html
2. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopridogrel. N Engl J Med 2009; 360(4): 354-362
3. Normile D. Consortium hopes to map human history in Asia. Science 2007; 306(5702): 1667.
4. Sgaier SK, Jha P, Mony P, et al. Biobanks in developing countries: needs and feasibility. Science 2007; 318(5853): 1074-1075 (Pubitemid 350134883)
5. Garrett L. Betrayal of trust-the collapse of global public health. New York: Hyperion 2000.
6. Weatherall DJ. Genomics and global health: time for a reappraisal. Science 2003; 302(5645): 597-599
7. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13(1): 43-61.
8. World Health Organization. Genomics and world health. Geneva: WHO (2002). Accessible from http://www.who.int/rpc/genomics-report.pdf
9. Pang T. Impact of pharmacogenomics on neglected diseases of the developing world. Am J Pharmacogenomics 2003; 3(6): 393-398 (Pubitemid 38044279)
10. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005; 6(3): 241-246
11. Hardy BJ, Séguin B, Goodsaid F, et al. The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet 2008; 9(Suppl. 1): S23-7.
12. Séguin B, Hardy BJ, Singer PA, et al. Genomic medicine and developing countries: creating a room of their own. Nat Rev Genet 2008; 9(6): 487-493 (Pubitemid 351693979)
13. Peterson-Iyer K. Pharmacogenomics, ethics and public policy. Kennedy Inst Ethics J 2008; 18(1): 25-56.
14. Holm S. Pharmacogenetics, race and global injustice. Dev World Bioethics 2008; 8(2): 82-88
15. Mcguire ML, Cho MK, McGuire SE, et al. The future of personal genomics. Science 2007; 317(5845): 1687.
16. World Health Organization. Primary health care - Now more than ever. Geneva: WHO 2008. Available from: http://www.who.int/whr/ 2008/whr08-en.pdf
17. Murray CJL, Lopez AD, Chin B, et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-1920 pandemic: a quantitative analysis. Lancet 2006; 368(9554): 2211-2218
18. Keeton K. South African doctors move quickly to contain new virus. Bull WHO 2008; 86(12): 912-913
19. Normile D. Scientists puzzle over Ebola-Reston virus in pigs. Science 2009; 323(5913): 451.
20. Layne SP, Monto AS, Taubenberger JK. Pandemic influenza: an inconvenient mutation. Science 2009; 323(5921): 1560-1561
21. Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008; 451(7181): 990-993 (Pubitemid 351301726)
22. St Louis ME, Hess JJ. Climate change: impacts on and implications for global health. Am J Prev Med 2008; 35(5): 527-538
23. World Health Organization. Preventing chronic diseases - A vital investment. Geneva: WHO 2005. Accessible from http://www.who.int/chp/chronic- disease-report/full-report.pdf
24. Kalow W. Pharmacogenetics and personalized medicine. J Clin Pharmacol 2002; 16(5): 337-342
25. Current Pharmacogenomics and Personalized Medicine homepage. Bentham Science Publishers. [Accessed: April 7, 2009]. Available from: http://www.bentham.org/cppm/
26. Blow N. The personal side of genomics. Nature 2007; 449(7162): 627-630
27. National Human Genome Research Institute. A catalog of published genome-wide association studies. [Accessed: April 6, 2009]. Available from: http://www.genome.gov/gwastudies/
28. Baker M. Genome studies: genetics by numbers. Nature 2008; 451(7178): 516-518
29. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 2008; 456(7223): 728-731
30. Anonymous. The germ of an idea. Economist 2007; 385(8557): 83-84.
31. Casanova JL, Fiechi C, Zhang SY, et al. Revisiting human primary immunodeficiencies. J Intern Med 2008; 264(2): 115-127
32. Sancho-Shimizu V, Zhang SY, Abel L, et al. Genetic susceptibility to herpes simplex virus 1 encephalitis in mice and humans. Curr Opin Allergy Clin Immunol 2007; 7(6): 495-505. (Pubitemid 350076444)
33. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321(5889): 691-696 (Pubitemid 36383736)
34. GOLD Genomes Online Database V2.0. [Accessed: April 8, 2009]. Available from: http://www.genomesonline.org/
35. NCBI Virus Genomes Database. [Accessed: April 8, 2009]. Available from: http://www.ncbi.nlm.nih.gov/genomes/genlist.cgi? taxid=10239&type= 5&name=Viruses.
36. Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324(5923): 55-59
37. FIND. Foundation for Innovative New Diagnostics. [Accessed: April 8, 2009]. Available from: http://www.finddiagnostics.org/
38. Nakamura S, Maeda N, Miron IM, et al. Metagenomic diagnosis of bacterial infections. Emerg Inf Dis 2008; 14(11): 1784-1786
39. Curing Malaria Together. Medicines for Malaria Venture (MMV). http://www.mmv.org/rubrique.php3?id-rubrique=15 [Accessed: April 8, 2009].
40. Global Alliance for TB Drug Development. [Accessed: April 8, 2009]. Available from: http://www.tballiance.org/home/home.php
41. African Network for Drugs and Diagnostics Innovation. [Accessed: April 8, 2009]. Available from: http://www.who.int/tdr/svc/research/lead-discovery- drugs/partnerships-networks#-African-Network-for
42. Aeras. Global TB Vaccine Foundation. [Accessed: April 8, 2009]. Available from:http://www.aeras.org/home/home.php
43. Chirac P, Torreele E. Global framework on essential health R&D. Lancet 2006; 367(9522): 1560-1561
44. Rosamond J, Allsop A. Harnessing the power of the genome in the search for new antibiotics. Science 2000; 287(5460): 1973-1976 (Pubitemid 30158665)
45. Haselden JN, Nicholls AW. Personalized medicine progresses. Nat Med 2006; 12(5): 510-511
46. Pene F, Courtine E, Cariou A, et al. Toward theragnostics. Crit Care Med 2009; 37(Suppl. 1): S50-8.
47. Pang T. Equal partnership to ensure that developing countries benefit from genomics. Nat Genet 2003; 33(1): 18. (Pubitemid 36068674)
48. Alwan A, Modell B. Recommendations for introducing genetic services in developing countries. Nat Rev Genet 2003; 4(1): 61-68 (Pubitemid 36043216)
49. Morel CM, Acharya T, Broun D. Health innovation networks to help developing countries address neglected diseases. Science 2005; 309(5733): 401-404 (Pubitemid 40994673)
50. Service RF. Surviving the blockbuster syndrome. Science 2004; 303(5665): 1796-1799
51. Goozner M. A prescription for public health. Nature 2008; 453 (7197): 855-856
52. Séguin B, Hardy BJ, Singer PA, et al. Universal health care, genomic medicine and Thailand: investing in today and tomorrow. Nat Rev Genet 2008; 9(Suppl. 1): S14-9.
53. Hardy BJ, Séguin B, Ramesar R, et al. South Africa: from species cradle to genomic applications. Nat Rev Genet 2008; 9(Suppl. 1): S19-23.
54. Séguin B, Hardy BJ, Singer PA, et al. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nat Rev Genet 2008; 9(Suppl. 1): S5-9.
55. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting anti-retroviral drug toxicity? J HIV Ther 2003; 8(2): 36-41.
56. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007; 3(1): 1-8. (Pubitemid 47307453)
57. PGENI. Pharmacogenetics for Every Nation Initiative. [Accessed: April 8, 2009] . Available from: http://pgeni.unc.edu/purpose.asp
58. World Health Organization. Everybody's business - strengthening health systems to improve health outcomes. Geneva: WHO (2007). Available from: http://www.who.int/healthsystems/strategy/everybodys-business.pdf
59. Pharmacogenetics: Ethical Issues. London: Nuffield Council on Bioethics 2003.
60. Lowrance WW, Collins FS. Identifiability in genomic research. Science 2007; 317(5838): 600-602
61. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases. J Am Med Assoc 2008; 299(11): 1320-1334
62. Anonymous. Taking your genes in hand. Economist 2007; 385 (8558): 86-87
63. Katsanis SH, Javitt G, Hudson K. A case study of personalized medicine. Science 2008; 320 (5872): 53-54
64. Dharmapalan B. Personalized genome game-a new social discrimination in the offing. Curr Sci 2008; 94(11): 1350-1351 (Pubitemid 351883989)
65. Prainsack B, Reardon J, Hindmarsh R, Gottweis H, Naue U, Lunshof JE. Personal genomes: Misdirected precaution. Nature 2008; 456(7218): 34-35
66. Guessous I, Gwinn M, Yu W, Yeh J, Clyne M, Khoury MJ. Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics 2009; 12(3): 142-148
67. Merikangas KR, Risch N. Genomic priorities and public health. Science 2003; 302(5645): 599-601.
68. Normile D. The promise and pitfalls of clinical trials overseas. Science 2008; 322(5899): 214-216
69. World Health Organization. International Clinical Trials Registry Platform (ICTRP). [Accessed: April 8, 2009]. Available from: http://www.who.int/ictrp/en/
70. Little J, Higgins JPT, Ioannidis JPA, et al. Strengthening the Reporting of Genetic Association Studies (STREGA)- An Extension of the STROBE Statement. PLoS Med 2009; 6(2): e1000022.
71. Urquhart J. The drugs not taken. Science 2008; 321(5890): 769.
72. Wasi P. Triangle that moves the mountain and health systems reform movement in Thailand. Bangkok: Health Systems Research Institute 2000.